Viatris' pain drug meets main goals of two late-stage trials
The company's shares were up 1.6% in premarket trading.
The drug was tested in one of the studies in patients who had surgery for the repair of hernia, while in the other, in those who had undergone a surgical procedure to correct bunions, a deformity at the big toe joint.
In both the studies, the drug led to improvement in pain compared to placebo, as measured by a commonly used scale to evaluate the effectiveness of pain treatments, called Sum of Pain Intensity Difference.
It also helped reduce usage of opioids, which are highly addictive, over the entire treatment phase.
"The data observed in two surgical models... is a critical step in the development of a safe and effective non-opioid option to address an important public health need," said Philippe Martin, Viatris' research and development chief.
Separately, the company also said that a lower dose version of its birth control patch, called Xulane, also met all the main goals of a late-stage study.
Viatris plans to seek the FDA's approval for the patch, branded Xulane Lo, in the second half of the year.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Reuters
a minute ago
- Reuters
French preliminary inflation at 0.9% in July, slightly above forecast
July 31 (Reuters) - French consumer prices rose slightly more than anticipated in July, preliminary data from statistics agency INSEE showed on Thursday. France's harmonised inflation rate, adjusted for comparison with other euro zone countries, was +0.9% year-on-year in July. A Reuters poll of 18 analysts had on average expected a rate of +0.8%, with estimates ranging from +0.4% to +1.0%.
Reuters
31 minutes ago
- Reuters
Shell's profit drops by almost a third but easily beats expectations
LONDON, July 31 (Reuters) - Shell's (SHEL.L), opens new tab second-quarter adjusted earnings, its definition of net profit, tumbled by almost a third on Thursday, dragged down by a drop in oil prices, but still easily beat analysts' forecasts. The oil major said it would maintain the pace of its share buyback programme at $3.5 billion over the next three months, the 15th consecutive quarter of at least $3 billion. Shell has, meanwhile, achieved $3.9 billion in cost cuts compared with 2022, part of a cost-cutting programme aimed at saving between $5 billion and $7 billion by the end of 2028. It recorded cash flow from operations of $11.9 billion in the quarter, down from $13.5 billion a year ago. Together with $2.1 billion in dividends, that brings shareholder distributions to 46% of operating cashflow, within its 40% to 50% guided range. Shell's adjusted earnings reached $4.264 billion in the second quarter, smashing the $3.74 billion average in an analyst poll provided by the company but down 32% from a year ago. Global benchmark Brent crude prices averaged around $67 a barrel during the April-to-June quarter, compared with $75 a barrel in the first quarter and $85 a year earlier. Crude oil prices fell in the quarter as OPEC+, made up of the Organization of the Petroleum Exporting Countries and allies such as Russia, began unwinding self-imposed production cuts aimed at supporting the market. Their most recent decision calls for an oil output increase of 548,000 barrels per day in August. Shell had guided in a trading update that it expected earnings to be hit by weaker trading in its integrated gas division and losses at its chemicals and products operations after an outage at its U.S. Monaca polymer plant.
Reuters
an hour ago
- Reuters
Shell beats profit expectations at $4.3 billion, keeps buybacks steady
LONDON, July 31 (Reuters) - Shell's (SHEL.L), opens new tab adjusted earnings, its definition of net profit, reached $4.264 billion in the second quarter, it said on Thursday, above the $3.74 billion average in an analyst poll provided by the company but down from $6.3 billion a year ago. Shell said it would maintain the pace of its share buyback programme at $3.5 billion over the next three months, the 15th consecutive quarter of at least $3 billion. Shell had guided in a trading update earlier this month that it expected quarterly earnings to be hit by weaker trading in its integrated gas division and losses at its chemicals and products operations. Global benchmark Brent crude prices averaged around $67 a barrel during the April-June quarter, compared with $75 a barrel in the first quarter and $85 a year earlier.
